ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Growth Hormone
Phase 3

Sermorelin

Sermorelin

Also known as: Geref, GRF 1-29, Sermorelin Acetate

Overview

Key Facts

Primary Goal: A 29-amino acid GHRH analog representing the shortest fully functional fragment of native GHRH

A 29-amino acid GHRH analog representing the shortest fully functional fragment of native GHRH. It was previously FDA-approved for diagnosing and treating GH deficiency in children before being discontinued for commercial reasons. Half-Life 10-20 minutes Typical Dose 200–500 mcg Frequency once daily before bed Cycle Length 3-6 months

Dosing Information

Half-Life

10-20 minutes

Typical Dose

200–500 mcg

Frequency

once daily before bed

Cycle Length

3-6 months

Administration Routes:

subcutaneous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F)
DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)
Duration2-4 weeks

Research Summary

Phase 3

Sermorelin was FDA-approved in 1997 under the brand name Geref for pediatric GH deficiency diagnosis and treatment. Clinical trials demonstrated its ability to restore physiologic GH secretion patterns. It was voluntarily withdrawn from market in 2008 for commercial reasons, not safety concerns, and remains available through compounding pharmacies.

Frequently Asked Questions

Common questions about Sermorelin

UK-Specific Information

Exclusive data points and guidance for UK residents using Sermorelin

UK Lab Testing

US Lab Testing

Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With